Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program Project for Developing Innovation Systems Ministry of Education, Culture, Sports, Science and Technology(MEXT) Science and Technology Policy Bureau University-Industry Collaboration and Regional R&D Division Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program 3-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8959, Japan Tel : +81-(0)3-5253-4111 2014.03 Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
30
Embed
Creation of Innovation Centers for Advanced Interdisciplinary ...
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1 2
Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
Project for Developing Innovation Systems
Ministry of Education, Culture, Sports, Science and Technology(MEXT) Science and Technology Policy Bureau University-Industry Collaboration and Regional R&D Division Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program3-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8959, Japan Tel : +81-(0)3-5253-4111 2014.03
東 京大 学The University of Tokyo
Creation of Innovation Centers forAdvanced Interdisciplinary Research Areas Program
INDEXCreation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
2006 2007 2008
1
The Ministry of Education, Culture, Sports, Science and Technology (MEXT) emphasiz-
es the importance of creating continuous innovation by making the best use of its ba-
sic scientific and engineering capabilities in order to secure a sustainable competitive
advantage for Japan in the international community.
Generating new knowledge by maximizing the effects of synergy through the fusion
of different disciplines is also required in order to meet diversified social needs. Being
aware of such needs, MEXT has operated since FY 2006 a program for the “Creation
of Innovation Centers for Advanced Interdisciplinary Research Areas.”
This program is expected to create R&D centers and strengthen the capacity of re-
searchers and engineering staff shouldering next-generation needs in advanced inter-
disciplinary research areas.
The aim of this program is to overcome the so-called “valley of death” through inte-
grated industry-academia collaboration focusing on future commercialization.
Twelve centers are currently being operated in advanced interdisciplinary research ar-
eas such as nanotechnology, biotechnology, IT, and the like, as well as in fields such
as engineering, medicine, pharmacology, and physical sciences. These centers strongly
promote R&D for creating innovation with enormous social and economic impact,
such as the creation of new industries that can be expected to emerge in 10–15 years,
through not only the involvement of universities but the active participation and com-
mitment of enterprises (with a matching fund format). Products have already been
commercialized in several areas. This program can be expected to become good prac-
tices for innovation creation in Japan.
Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
Project for Developing Innovation Systems
Project Guide 02
Locations 03
Adopted FY2006
Kyoto University Innovative Techno-Hub for Integrated Medical Bio-Imaging 04
The University of Tokyo COE for Nano Quantum Information Electronics 08
Hokkaido University 12
Tokyo Women’s Medical University 16
In-Depth Focus � 20
Adopted FY2007
Osaka University Photonics Advanced Research Center� 22
The University of Tokyo Translational Systems Biology and Medicine Initiative� 26
Tohoku University R&D Center of Excellence for Integrated Microsystems� 30
Kyushu University Innovation Center for Medical Redox Navigation� 34
Kyoto University � 38
In-Depth Focus � 42
Adopted FY2008
Yokohama City University � 44
� 48
Kobe University Innovative Bio Production Kobe (iBioK) � 52
In-Depth Focus � 56
INDEX
March 2014University-Industry Collaboration and Regional R&D Division Science and Technology Policy Bureau Ministry of Education, Culture, Sports, Science and Technology
Kyoto�U�adopted�FY2007�is�here
The Matching Program for Innovations in Future Drug Discovery and Medical Care
Advanced Interdisciplinary Center for the Establishment of Regenerative Medicine
Innovation Center for Immunoregulation Technologies and Drugs
Establishment of Research Center for Clinical Proteomics of Post-Translational Modifications
Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)
National Institute of Advanced Industrial Science and Technology
2 3
ProjectsCreation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
2006 2007 2008
OverviewCreation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
2006 2007 2008
東 京大 学The University of Tokyo
拠 点
Tokyo Women’s Medical University
Advanced Interdisciplinary Center for the Establishment of Regenerative Medicine
Collaborating Organizations : JEOL Ltd., Shimadzu Corporation, M i t s u b i s h i T a n a b e P h a r m a Corporation, Taiho Pharmaceutical Co., Ltd., HOYA Corporation, Fuji Electric Co., Ltd., NOF Corporation, Kyushu Electric Power Co., Inc.
Innovation Center for Immunoregulation Technologies and Drugs
Collaborating Organizations : Astellas Pharma Inc.
Yokohama City University
Establishment of Research Center for Clinical Proteomics of Post-Translational Modifications
Collaborating Organizations : Medical ProteoScope Co., Ltd., Lion Corporation, FUJIFILM Corporation, Eisai Co., Ltd., FANCL Corporation, TOSOH Corporation, Sekisui Medical Co., Ltd., Toyama Chemical Co., Ltd, CellFree Sciences Co., Ltd.
Osaka University
Photonics Advanced Research Center
Collaborating Organizations : Shimadzu Corporation, Sharp Corporation, Nitto Denko Corporation, Mitsubishi Chemical Group Science and Technology Research Center, Inc., IDEC Corporation
The University of Tokyo
COE for Nano Quantum Information Electronics
Collaborating Organizations : Sharp Corporation, NEC Corpo-ration, Hitachi, Ltd., Fujitsu Laboratories Ltd., QD Laser, Inc.
The University of Tokyo
Translational Systems Biology and Medicine Initiative
In the 3 years before the review About 300 million yen per year
After full-scale implementation About 500–700 million yen per year
During the initial 3 years, centers that have made proposals are shortlisted.A review is conducted in the 3rd year (after 2.5 years and 3.5 years) to narrow down the list by two-thirds.Themes that proceed to actual implementation shall continue to be imple-mented over the next 7 years. A total of 21 themes were selected between 2006 and 2008. Currently, 12 of these are underway.
Universities, inter-university research institute corporations, national research institutes, and incorporated administrative agencies(Participants are obliged to come up with joint proposals with the industrial world, which is also expected to shoulder a reasonable amount of the cost.)
Participants
先端融合拠点形成
次世代を担う研究者・技術者の育成
産学協働で社会・経済的インパクトのある
イノベーションを推進する拠点を形成
要素技術(企業、大学)の
参画
他先端領域との連携
協働体制の構築
開発力(企業)
先端的なコア技術(大学)
ER1 R2
CNB
R3R4N
Y
Creation of Centers for Advanced Interdisciplinary ResearchCreate centers to promote innovations that have social and economic impact
through collaboration between industry and academia.
This program aims to support the creation of innovation centers that have significant social and
economic impact, such as the generation of new industries. The program will achieve this goal by
matching academia with industries in advanced interdisciplinary research areas considered to be
especially important for innovation.
To overcome the “valley of death,” creating R&D innovation centers to conduct basic research through industry-academic collaboration
Based on collaboration between industry and academia, create a system with the seeds sown by universities as its core, in order to realize innovation in advanced interdisciplinary research areas.
The Matching Program for Innovations in Future Drug Discovery and Medical Care
54
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
Kyoto UniversityInnovative Techno-Hub for Integrated Medical Bio-Imaging
Fusion of Kyoto University’s integrated scientific-technological knowledge and excellent clinical research achievements with the collaborating organization’s technical strengths in product development to create the social value through the realization of innovative imaging-diagnosis techniques and modalities.
ORGANIZATION
Name Kyoto University
U R L http://ckpj.t.kyoto-u.ac.jp/?lang=en
Address Yoshida Hon-machi, Sakyo-ku, Kyoto 606-8501, Japan TEL. +81-75-753-4896 FAX. +81-75-753-9147Overall Person-in-charge Hiroshi Matsumoto (President, Kyoto University)
Researcher (Representative) Nagahisa Yoshimura (Professor, Graduate School of Medicine)/
Teruyuki Kondo (Professor, Advanced Biomedical Engineering Research Unit)
New Optical Coherence Tomography Equipment (OCT-HS100)
An Image of the Breast Cancer Examination with PAM
Expected Market Scale/Expected Achievement Period
600 billion yen (global market scale) /4 years after end of
implementation period
Results to Date We have developed the state-of-the-art
atomic magnetometers achieving the top level sensitivity
in the world. We also have developed a compact mod-
ule-type atomic magnetometer. Using the atomic mag-
netometers, NMR signals have been observed under low
magnetic field conditions. In addition, both the imaging
of magnetocardiographic distributions and the measure-
ment of neuro-magnetic fields
are successful in humans.
A Module-type Atomic Magnetometer
A Photoacoustic-Magnetic Resonance Dual Im-aging Probe
Collaborating Organization : Canon Inc.
Aspect Analysis Based on the Features of Lung Nodule
98
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
The University of TokyoCOE for Nano Quantum Information Electronics
ORGANIZATION
Name The University of Tokyo
U R L http://www.nanoquine.iis.u-tokyo.ac.jp/index-e.html
Address 4-6-1, Komaba, Meguro-ku, Tokyo TEL. 03-5452-6920 FAX. 03-5452-6921
Development of technologies to realize a safe, low energy consumption, and ambient IT society through a combination of nanotechnology, quantum science, IT, and electronics
Overall Person-in-charge Junichi Hamada (President, the University of Tokyo)
Researcher (Representative) Yasuhiko Arakawa (Professor, Institute of Industrial Science)
Implementation Period FY2006 – FY2015
Collaboration System1
2 Overall Concept
B y t h e d e v e l -
opment of in-
novat ive bas ic
technologies and
the nu r tu r i ng
of research manpower, we aim to realize a
next-generation information network system
that satisfies the ultra-broadband, ultra-safe
and ultra-energy-efficient (low power con-
sumption) requirements of the ubiquitous
information society of the future.
Within the university we are consolidating
knowledge on nanotechnology, quantum
science, and IT, and striving to build up both
international and national collaborations
with influential researchers and institutions
within and outside Japan. Our core research
is being carried out on next-generation nano-
electronics, focusing on quantum dot lasers,
nano-quantum information electronics such
as encrypted quantum communications, and
the basic technologies in quantum informa-
tion science that support all of these areas.
Advanced lectures that provide a broad over-
view of these topics are given in the science
and engineering schools, and intensive indus-
try-orientated lectures are organized with col-
laborating organizations in order to develop
well-rounded personnel.
Intellectual property agreements among the
collaborating organizations are unified, and
we are also carrying out Intellectual property
reform making use of special zones within the
university. We are striving to attract excellent
researchers to the center.
■ 7th Year (FY2012)
1 Expand the market for quantum dot lasers and build a foun-
dation for the creation of innovation using quantum mechanical
devices.
2 Verify the high-speed behavior of organic CMOS circuits
and establish the basic technologies for large-area organic
electronics.
3 Achieve quantum key distribution over long distances (i.e., a
transmission distance of 50 km) using single-photon technologies
and demonstrate commercialization possibilities for encrypted
quantum communications.
■ 10th Year (FY2015)
1 Expand the market for industrial and consumer applications of
Fusion of next-generation drug discovery using protein modification technologies and personalized medicine using light and radiation measurement technologies
Drug Discovery Research Project Leader : Yasuyuki Igarashi (Specially Appointed Professor, Frontier Research Center for Post-genome Science and Technology ) / Medical Care Research Project Leader : Nagara Tamaki (Professor, Graduate School of Medicine)
Towards the establishment of a drug discovery foundation that enables the continuous creation of potential drug candidate compounds
Make use of the strengths of Hokkaido University in researches of lipids, glycans, structural biology, etc., to explore new
potential drug targets, conduct drug discovery research based on advanced protein structures, promote investigative re-
search and development of research tools for identifying diseases and creating biomarkers for drug discovery, and take
on the challenge of creating potential pharmaceutical compounds that can advance to the clinical trial stage, with the
ultimate aim of establishing a drug discovery foundation that enables the continuous creation of potential drug candidate
compounds. In addition, expand basic and clinical research with a focus on the development of regenerative medicine.
Collaborating Organization : Hitachi, Ltd.
Development of non-invasive personalized medical care beneficial to patients
Based on component technologies such as photonic/RI imaging technology, aim for the construction of a new medical
process and development of medical devices that make non-invasive personalized medical care that is beneficial to patients
a reality, and take up the challenge of conducting R&D in various areas in partnership with collaborating organizations.
Results to Date The use of the virus library in Hokkaido
University contributed to the development of anti-influ-
enza drugs launched in 2010. Based on the results ob-
tained in this project, one potential drug compound has
also entered pre-clinical trial testing. Besides this, three
new drug discovery programs
have also been started (for two
infectious disease drugs and
one lifestyle-related disease
drug). Furthermore, drug dis-
covery group has started a bio-
1 Development of pharmaceutical products with new action mechanisms
2 Development of new carbohydrate microarray
Results to Date Based on the
results obtained in this project,
Sumitomo Bakelite Co., Ltd.
started sales of a carbohydrate
microarray in FY2011.Collaborating Organization : Sumitomo Bakelite Co., Ltd.
Collaborating Organization : Shionogi & Co., Ltd.
marker exploration project with Shionogi & Co., Ltd. that
is spearheaded by its wholly owned U.S. subsidiary Ezose
Sciences, which was established in Feb 2009.
Results to Date Research that applies semiconductor
technology in medical treatment has been advanced
through the development and clinical application of the
world’s first PET/SPECT that uses a semiconductor de-
tector. Due to the high-definition of the detector, local
diagnosis of the hypoxia region in head and neck cancer
is made possible, and this has been applied in radiation
therapy planning. As a ripple effect, this has also proven
useful in the detection of radia-
tion after the Great East Japan
Earthquake and the commercial
sales of semiconductor radiation
detectors and modules.
Development of high-definition PET/SPECT using semiconductor detection technology, and related clinical applications
3
5
1716
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
Tokyo Women’s Medical UniversityAdvanced Interdisciplinary Center for the Establishment of Regenerative Medicine
ORGANIZATION
Name Tokyo Women’s Medical University
U R L http://www.twmu.ac.jp/ABMES/CSTEC/ja
Address 8-1, Kawada-cho, Shinjuku-ku, Tokyo TEL. 03-3353-8111 FAX. 03-3359-6046
Creation of innovation centers for the development, spread, and industrialization of world-leading and multi-disciplinary regenerative technology through the fusion of cell sheet engineering technology and medical science
Overall Person-in-charge Hiroshi Kasanuki (President, Tokyo Women’s Medical University)
Researcher (Representative) Teruo Okano (Professor, Tokyo Women’s Medical University)
Implementation Period FY2006 – FY2015
Collaborating Organizations : Dai Nippon Printing Co., Ltd.,
CellSeed Inc., Hitachi, Ltd.
■ 7th Year (FY2012)
1 Carry out the world’s first human clinical research on cell sheet
regeneration for esophageal cancer, heart failure, periodontal
disease, pneumothorax, and the like, in addition to achieving the
world’s first approval for cornea regeneration using cell sheets.
2 Establish a manpower development and support system with
on-the-job trainings of new types of regenerative medicine doc-
tors and researchers based on a new setup for industry-academia
collaboration and interdisciplinary medical engineering.
■ After Project Ends (around 2025)
1 Regenerative medicine using cell sheets for a variety of tissue
and internal organs will be made available to patients at clinical
sites, including those overseas.
2 A regenerative medicine industry using cell sheets to achieve
radical treatment will pull along the pharmaceutical industry and
achieve greater development through the fusion of advanced
technologies and new fields.
■ 10th Year (FY2015)
1 Promulgate the use of cell sheets worldwide in addition to
promoting clinical research and clinical trials in regenerative
medicine using cell sheets for various tissue and internal organs.
2 Achieve a breakthrough that exceeds traditional boundaries
in 2D tissue cultivation and establish the basic technologies for
realizing organ regeneration after tissue regeneration. Promote
the sharing of ideas, technologies, and aims among doctors and
researchers and create industrial innovations for a society that is
based on regenerative medicine using cell sheets.
Collaboration System1
2 Overall Concept
Regenerative medicine is attracting much
attention as a next-generation radical cure
amid heightening expectations for treatments
to substantially improve the QOL of patients
suffering from serious ailments and intrac-
table diseases. This center aims to become
a research center for creating innovations
that integrate various advanced technologies
across different domains deemed necessary
for making regenerative medicine truly feasi-
ble. We have already created “cell sheet engi-
neering,” and after verifying its effectiveness
and safety in animal experiments, we have
been successful in treating the ailments of
patients. This socially and medically unprece-
dented treatment method has been achieved
through the combined efforts of many re-
searchers and doctors in different domains,
and a next-generation, interdisciplinary
medical engineering center that has hitherto
not been seen has been formed. In order to
further develop and spread this innovation,
industrialization through mass production
and generalization of the existing system is
necessary. Further manpower development
and building of international competitiveness
is aimed for, together with the collaborating
organizations.
RESEARCH THEME
19
3 Development of support technologies for medical treatment using cell sheets
In-Depth Focus 04 Tokyo Women’s Medical University
04
03
In-Depth Focus 03 Hokkaido University
In-Depth Focus 02
02
01
In-Depth Focus 01 Kyoto University
The University of Tokyo 東 京大 学The University of Tokyo
New Imaging-Diagnosis Equipment — Optical Coherence TomographyThe research group’s breakthrough in Optical Coherence Tomography
(OCT), simultaneously bringing further improvements in resolution and
imaging speed, the OCT-HS100 marketed by Canon in Sep. 2012, is
expected to lead to a high level eye fundus diagnostic modality with the
ability to detect signs of sight threatening diseases appearing on the
fundi.
Clinical Research in Progress — Photoacoustic Mammography(introduced with a newspaper, the Nihon Keizai Shimbun, on June 29, 2010)The research group is investigating a novel technology which integrates
Ultrasound and optical imaging (US/PAT), and a prototype model of the
Photoacoustic Mammography (PAM) has been introduced at the Clinical
Research Center for Medical Equipment Development. A clinical study of
PAM, which enables the visualization of neovascular networks of cancer,
has been started to demonstrate its usefulness in the early detection and
functional diagnosis of cancer without X-ray irradiation.
The ultimate goal of the project is to create a “healthy society” by promoting cutting-edge research and development, improv-ing quality of life (QOL) and reducing medical expenses for the aging society, while fostering talented researchers in an inter-disciplinary research area of medicine and engineering.
New Optical Coherence Tomography Equipment (OCT-HS100)
An Image of the Breast Cancer Examination with PAM
Innovative Techno-Hub for Integrated Medical Bio-Imaging
The Matching Program for Innovations in Future Drug Discovery and Medical Care
COE for Nano Quantum Information Electronics
Establishment of the Shionogi Inno-vation Center for Drug DiscoveryThe Shionogi Innovation Center for Drug Discovery was established in 2008 by Shionogi & Co., Ltd. as a profes-sional center of collaboration between industry and academia to nurture the seeds of technology sown by Hokkaido University and discov-er future drug discovery prospects. This 5-story center with a building area of 600 m2 and a floor area of 2,790 m2 is the first research facility from the private sector built within the grounds of a national university in Japan. Development of high-definition semiconductor PETThe clinical research system of Hokkaido University was en-hanced, and a total of about 680 clinical cases, which exceeded the number planned initially, were studied during the develop-ment of the high-definition semiconductor PET. The development framework has also been further enhanced through the devel-
Prototype models for semiconductor PET equipment and SPECT equipment used for brain
opment and introduction of a prototype semicon-ductor gamma camera in the Hokkaido University Hospital by Hitachi, Ltd., the commercialization of a radiation detector module, and other initiatives.Long-term human resources development for life sciencesEvery year, joint lectures for the Graduate Schools of Hokkaido University such as the “Shionogi Special Lecture on Drug Discov-ery Science,” the “Molecular Imaging Seminar,” and “Advanced Radiology, Nuclear Medicine, and Radiation Oncology” are conducted by more than 80 researchers from collaborating com-panies. This far, about 500 graduate students have attended the lectures in the last 5 years. A center for continued cooperation with the companies in developing such long-term manpower for the life science sector is also being formed.Advanced Radiation Therapy Project: Real-time Tumor-tracking with Molecular Imaging Technique Professor Hiroki Shirato proposed joint research on proton beam treatment to Hitachi, Ltd., and they have been developed many equipment. He was also the core researcher of the Funding Program for World-Leading Innovative R&D on Science and Tech-nology (FIRST program) in FY2009 under the title “Advanced Ra-diation Therapy Project: Real-time Tumor-tracking with Molecular Imaging Technique” selected by the Cabinet Office as one.
Posters advertising on the joint lectures conducted by the graduate school in FY2013
Advanced Interdisciplinary Center for the Establishment of Regenerative MedicineCOE for Nano Quantum Information Electronics
20 21
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
22
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
23
Osaka UniversityPhotonics Advanced Research Center
tion ultraviolet lasers at a practical level and promoted to
commercialize it.
Collaborating Organizations : Sharp Corporation
Next-generation energy-saving, high-capacity optical storage and wavelength-conversion crys-tals for next-generation UV Laser for use in precise device- fabrication and semiconductor pro-cess-evaluation
2
3
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
26 27
The University of TokyoTranslational Systems Biology and Medicine Initiative
Development of minimally invasive, high-precision diagnosis and therapies through the fusion of integrated technologies in diagnosis and treatment with transformative technologies and antibody creation for cancer and lifestyle diseases
ORGANIZATION
Name The University of Tokyo
U R L http: //www.tsbmi.m.u-tokyo.ac.jp/index.html
Address 7-3-1, Hongo, Bunkyo-ku, Tokyo TEL. 03-5800-9079 FAX. 03-5800-9081 Overall Person-in-charge Junichi Hamada (President, the University of Tokyo)
Researcher (Representative) Takashi Kadowaki (Professor, Graduate School of Medicine)
Implementation Period FY2007 – FY2016
■ 7th Year (FY2013)
1 Begin independent, doctor-led clinical trials for minimally
invasive, high-precision diagnostic and treatment equipment
using labelled antibodies based on the pre-targeting of cancer.
Complete animal trials for diagnostic and treatment systems that
combine antibody drugs with an HIFU (High-Intensity Focused
Ultrasound ) endoscope system.
2 Obtain pharmaceutical approval and commence sales for ex-
panded indications of diagnostic drugs for Type 2 diabetes and
complete independent, doctor-led clinical trials for low molecular
drugs.
■ 10th Year (FY2016)
1 Begin clinical trials based on the Pharmaceutical Affairs Act
for minimally-invasive, high-precision diagnostic and treatment
equipment using labelled antibodies based on the pre-targeting
of cancer. Enter into clinical trials based on the Pharmaceutical
Affairs Act for diagnostic and treatment systems that combine
antibody drugs with an HIFU (High-Intensity Focused Ultrasound)
endoscope system.2 Enter into independent, doctor-led clinical trials for antibody
drugs and clinical trials based on the Pharmaceutical Affairs Act
for low molecular drugs for Type 2 diabetes.
Collaboration System1
2 Overall Concept
This research aims at the
development of local-
ized treatment devices
and cell-specific drugs
against diseases in the
human body, as opposed to traditional inva-
sive medical devices and non-selective drugs
with many side effects. It is also a goal to
build a development center to provide safe,
secure, and compassionate medical treat-
ment. For these purposes, we will make use
of the features of the different missions that
companies shoulder in clinical research (pa-
tient specimens, access to information), basic
research (ability to obtain genes, cells, etc.;
theoretical and system operation capability)
and commercialization (ability to provide
funds for clinical trials and commercialization
technologies, etc.). We will break down the
traditional barriers inherent in one-to-one
joint research between universities and corpo-
rations and establish a new industry-academia
partnership system to advance research and
development in a cyclic manner from “clinical
to basic to commercialization to clinical.” This
will be achieved with the university acting as
platform for interdisciplinary research by the
university’s various laboratories, which possess
basic core technologies and information, and
numerous companies possessing world-lead-
ing elementary core technologies.
Collaborating Organizations : Forerunner Pharma Research
Co., Ltd., Olympus Corporation, Sekisui Medical Co., Ltd.,
and simulation of the immune system, and the system and tech-
nology for clinical specimen analysis to search bio-marker and
improve the predictability in the pre-clinical stage so as to in-
crease the success rate in clinical trials.
■ After Project Ends (around 2021)
1 Launch more than three drugs onto the market with indica-
tions in diseases such as rheumatoid arthritis, systemic lupus ery-
thematosus and allergy and as immunosuppressant.
2 Based on the AK project model, will establish a drug R&D
center at Kyoto University, which continues to support industry-
academia collaboration and enhance international competitive-
ness of drug industry in Japan.
■ By 10th Year (FY2016)
1 Will complete evaluation of efficacy and safety of candidate
compounds, biologics and new medical technology in pre-clini-
cal test and will create more than three drugs to launch. Phase I
clinical trials on drug candidates ready by this time will be started
either by the company or at the Translational Research Center of
Kyoto University.
2 Will produce more than 20 medical scientists and other tal-
ents specialized in drug discovery as senior researchers and ten-
ured staffs in universities, companies, government agencies, and
other organizations.
The purposes of the AK project are i) devel-
opment of “next-generation immunoregula-
tory medicines” by combining drug discovery
technologies of Astellas Pharma and basic
and clinical research in Kyoto University Grad-
uate School of Medicine and Kyoto University
Hospital, ii) creating a model of industry-
academia collaboration for drug discovery in
the post-genome era, and iii) nurturing sci-
entists and other talents specialized in drug
discovery. Specifically, we have established
the Fusion labolatory in the campus of Kyo-
to University Graduate School of Medicine,
where researchers from Graduate School of
Medicine of Kyoto University work togeth-
er with researchers from Astellas Pharma in
order to carry out interdisciplinary research
and establish an efficient drug discovery R&D
system. Through these efforts, we aim to de-
velop innovative drugs in immunology area
to fulfill unmet medical needs in intractable
diseases such as allergies, autoimmune dis-
eases, chronic inflammatory diseases, chronic
infectious diseases, organ transplantation and
cancer. By such accomplishment, we will con-
tribute to the health and welfare of human
beings, and strengthen the international com-
petitiveness of the pharmaceutical industry in
Japan. Furthermore, we nurture and produce
scientists and other talents specialized in drug
discovery, who possess integral knowledge
and skills in medicine, drug discovery, intel-
lectual property and other related fields, and
who function as the interface between indus-
try and academia to promote drug discovery
in future.
Developping “Next-generation immunoregulatory therapeutics” by combining drug discovery technologies of Astellas Pharma and medical research of Kyoto University
RESEARCH THEME
41
3 Discovery of new drugs for atopic dermatitis
Keratinocytes in the skin
ep i the l ium funct ion as
a barrier against foreign
substances. In atopic der-
matitis, this keratinocyte
barrier is impaired because
o f down- regu la t ion o f
expression of filaggrin, a
cross-linker of keratin and a source of natural moisture
substances. At this project, we collaborate with De-
partment of Dermatology, Kyoto University Hospital, to
create an innovative drug that is capable of restoring im-
paired skin barrier in atopic dermatitis patients by upreg-
ulaiton of filaggrin expression and therefore differs from
steroids traditionally used in this disease.
Social Value Improve QOL of patients.
Economic Value As an orally active drug, substitute for
steroid ointment and make a new market.
Expected Market Scale/Expected Achievement Period
106.8 billion yen/year (Japan, the U.S., Europe); expected
launch in 2027, 11 years after the end of the implemen-
tation project
Results to Date Obtained a tool compound that upreg-
ulates the filaggrin expression in cultured skin cells and
shows improvement of the conditions in a mouse model
of atopic dermatitis. Large-scale compound exploration
on the target molecule of this compound is being imple-
mented.
40
Kyoto UniversityCenter for Innovation in Immunoregulatory Technology and Therapeutics (AK project)
1 Discovery of new drugs for rheumatoid arthritis (RA)
Rheumatoid arthritis (RA) is a disease of inflammation
of the synovial membrane in the joint, causing swelling,
continuous inflammation, pain, and deformation of af-
fected joints. While introduciton of anti-TNF therapy has
significantly improved its treatment, the effectiveness
and remission rate are still insufficient, and infection
caused by immunosuppression also occurs. At this pro-
ject, we therefore extract information thorugh analysis
of patient samples and create a novel type of drugs that
work directly on synovial membrane to suppress inflam-
mation and prevent joint damage.
Social Value Improvement in QOL of RA patients and
loss of the social labour force due to this disease by
achievement of higher remission rate in RA patients
including those unresponsive to existing drugs (such as
anti-TNF drugs).
Economic Value Reduction in costs for treating RA pa-
tients by decreasing the number of surgeries for synovial
membrane removal and joint replacement for patients
unresponsive to existing drugs as well as avoiding infec-
tions accompanying existing drugs, and by increasing
the proportion of patients with remission and drug-free
maintenace.
Expected Market Scale/Expected Achievement Period
268.7 billion yen/year (Japan, the U.S., and Europe);
expected launch in 2026, 10 years after the end of the
project
Results to Date Identified a target molecule by analysis
on synovial membrane tissue of RA patients, the anti-
body against which suppresses thickening of human syn-
oviocytes and shows high effectiveness in animal model
of the disease. Various lines of studies are being carried
out to develop this antibody as a clinical medicine.
2 Discovery of new drugs for systemic lupus erythematosus (SLE)
SLE is triggered by deposition of immunocomplex of cell
components and their auto-antibodies in the tissues such
as kidney, skin and brain, which eventually causes injury
of these tissues by inducing lymphocyte attack. SLE is
frequent in pubescent and post-pubescent females. The
etiology of SLE is not yet known, and symptoms differ
from patient to patient. At this project, we combine
analysis of its pathogenesis by basic immunology, analy-
sis of patient specimens with clinicians for validation and
patient stratification, and analysis of therapeutic efficacy
of antibodies created by Astellas Pharma in animal mod-
els to develop new treatment for this intractable disease.
Social Value Due to its superior therapeutic effect and
excellent safety, the drug can substitute for current drugs
including cyclophospha-
mide and MMF and be
expected to administer
sa fe l y to women o f
fertile capacity, thus ex-
panding the number of
applicable patients.
Economic Value Drastic
reduction in the cost for
SLE patients by reducing
the dose of steroid, which is not possible with existing
drugs, and preventing its adverse effects such as bone
fracture, infection, hypertension, and hyperlipidemia.
Collaborating Organizations : Astellas Pharma Inc.
Collaborating Organizations : Astellas Pharma Inc.
Expected Market Scale/Expected Achievement Period
105.8 billion yen/year (Japan, the U.S., Europe); expected
launch in 2027, 11 years after the end of the project.
Results to Date Identified a new drug target and mecha-
nism that may cause kidney injury and facilitate autoanti-
body production from the findings of basic immunology
research. An antibody against this molecule improved the
pathology in an SLE animal model. Creation of a human
antibody is in progress.
Collaborating Organizations : Astellas Pharma Inc.
4342
06
In-Depth Focus 06
In-Depth Focus 05 Osaka University
05
Tohoku University
07
In-Depth Focus 07
The University of Tokyo 東 京大 学The University of Tokyo
The keyword for emerging industrial technology in this 21st century is photonics. Osaka University’s Photonics Advanced Re-search Center aims to innovate science and industries by combining photonics, nanotechnology and biotechnology.
Together with Shimadzu Corporation, one of the member companies, this project pursued applied research on plas-ma photonics to develop the gas chromatograph Tracera, which features significantly enhanced detection sensitivity and is now marketed throughout the world by Shimadzu Corporation. The system is also capable of handling more samples than those with conventional detection methods.
Commercialization of tip-enhanced Raman scattering nanomicroscope
Productization of a new high sensitive gas chromato-graph system
Photonics Advanced Research Center Photonics (Science and Technology of light)
Kyushu University
08
Prototype of portable ReMI equipment with magnetic circuit
In-Depth Focus 08
Innovation Center for Medical Redox Navigation
towards the development of drugs and the establishment
of early diagnosis and treatment methods for redox-re-
lated diseases. Thus far, development of redox measuring
technology using the Overhauser effect has been carried
out, and a new type of MRI equipment (ReMI) in which
the magnetic circuit moves precisely has been developed.
This equipment allows the disease mechanism to be un-
derstood and visualized, and this is further expected to
lead to a new kind of medical diagnosis technology and
drug efficacy image analysis in drug development, includ-
ing with regard to anti-oxidation drugs.
Kyushu University Hospital, west wing “Innovation Center for Medical Redox Navigation”
R&D Center of Excellence for Microsystem Integration Research InitiativeDevelopment of integrated micro-biosensor system (through industry-industry-academia collaboration)
Jun 2, 2012 Nikkan Kogyo Shimbun
Manufactured bio-LSI measurement system (the LSI in the newspaper article photo is built-in)
Tohoku UniversityBio-sensing research based on electrochemical reaction using a 2D array LSI
Roles in industry - industry - academia collaboration
Development of device package and measurement system
Japan Aviation Electronics Industry
ToppanLSI design and creation using shared wafer sysytem
In recent years, excessive free radicals have been pro-
duced due to various changes in environmental factors
and unhealthy lifestyle, resulting in a breakdown of the
redox balance. As a result, the possibility that cancer,
lifestyle diseases, heart diseases, and the like may arise
has been pointed out. For example, 60% of the deaths
in Japan are said to be related to lifestyle diseases, and
thus the creation of advanced interdisciplinary medicine
focusing on redox is thought to be a national priority.
In this research center, researchers in medicine, phar-
macological, agriculture,
and engineering gather at
dedicated laboratories (about
2,000 m2) on the 5th and
6th floors of the west wing
within the university hospital
campus to carry out research
with the aim of creating ad-
vanced interdisciplinary med-
ical research areas oriented
The project succeeded in product development of tip-en-hanced Raman scattering microscope that utilizes light intensity enhancement by plasmon resonance at nano-meter scale. The product is now to be sold from a startup company. The technology has been under basic research for 20 years. The manufacturing of sharp nano-structured metal probes is one of the key technologies.
The system is made up of 20x20 current detection arrays, ampli-fication electrodes and LSI on top of which liquid reservoirs (with liquid specimens inside) are constructed. By capturing the chang-es in the current due to the electrochemical reaction that occurs in liquid specimens such as an enzyme in the reservoirs, DNA, bio-molecules, etc., the analysis of the behaviour and identifica-tion of type can be carried out in real time.
Translational Systems Biology and Medicine Initiative
【Participating in national politics】Advisor to the Office of Healthcare Policy un-der the Cabinet Secretariat: Yoichiro Matsumoto (Vice President, The University of Tokyo; Professor, School of Engineering)
Deputy Center Director (for Medical Devices), Phar-maceuticals and Medical Devices Agency (PMDA) : Ichiro Sakuma (Deputy Head of Research Center)
In an ageing society such as Japan where the number of deaths is increas-ing rapidly, the main causes of death are cancer, stroke, and heart diseas-es caused by lifestyle diseases. Treatments are invasive, with significant side effects, and the financial situation is dire due to high medical costs. In addition to systematically and comprehensively identifying cell-specific target proteins in cancer and lifestyle focal lesions based on translational systems biology and medicine, this center also aims to commercialize in-novative drugs and medical devices at a low cost and with few side effects by combining both diagnosis and treatment and by fusing less invasive, high-precision medical devices with imaging using an artificial protein probe together with collaborating organizations. The head of the research center, Professor Takashi Kadowaki, is a preeminent scholar in diabetes research who has achieved significant results and made numerous contri-butions over many years in the medical world. In 2010, 2011, and 2013, he was awarded the Purple Ribbon Medal, the Takeda Medical Science Prize, and the Japan Academy Award, respectively.
In the development and analysis of bio-marker measurement technology using clinical specimens, the development of the LCMS-8050 mass spectrometer, which provides sensitivity that is 10 times higher than that of existing models, has been successfully completed ahead of schedule, and sales were launched by Shimadzu Corporation on Aug 22, 2013. Furthermore, using this device, the possibility of BNP (5-32) and BNP (3-32) becoming new bio-markers for coronary restenosis was also demonstrated (Clinical Chemistry published May 13, 2013, as doi: 10.1373/clinchem.2013.203406).
Recent well-noted achievements
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
4544
Yokohama City UniversityEstablishment of Research Center for Clinical Proteomics of Post-Translational Modifications
Development of analytical technology by combining technologies in the medical, pharmaceutical, scientific, and engineering fields
Results to Date Abnormal PTM proteins related to can-
cer, neuropsychiatric disorders, and the like have been
detected and identified using basic technologies that
have been developed. The relationship between disease
and detected proteins has also been verified, and po-
tential biomarker proteins that can be used in diagnosis
have been discovered. Furthermore, many proteins that
have a high possibility of becoming drug targets have
been identified. Meanwhile, significant results have been
obtained in the screening of drug compounds that target
proteins related to prostate cancer, HIV, intractable men-
tal disorder, rheumatoid arthritis, Huntington’s chorea,
medulloblastoma, and the like.
2
4948
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
4948
National Institute of Advanced Industrial Science and Technology (AIST)Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)
ORGANIZATION
Name National Institute of Advanced Industrial Science and Technology (AIST)
equipment and time division multiplexing switches.
2 Carry out an actual operational demonstration of an optical
path network in the Tsukuba region using developmental tech-
nologies to verify low power consumption and large transmission
capacity.
■ After Project Ends (around 2023)
1 Growing in the use of dynamic optical path networks in actual
networks.
2 Promote research and development in communication tech-
nologies that can meet the requirements of society as an innova-
tion center based on the technologies cultivated in the research
center.
■ 10th Year (FY2017)
1 Upgrade the developmental technologies and create products
such as dynamic ROADM, wavelength selection switches, and
small-scale matrix switches.
2 Verify the ultra-low power consumption and convenience of
a dynamic optical path network in applications such as video
transmission through a field verification test over a wide area.
Collaboration System1
2 Overall Concept
In recent years, the volume of information
flowing through networks has increased rap-
idly, and thus the power consumption of the
entire network, including routers, has also
been increasing. To realize an information
society that can continue to grow on a sus-
tainable basis, it is crucial to drastically reduce
the energy consumed by networks. This re-
search center aims to resolve this problem by
developing a dynamic optical path network
technology whose energy efficiency is on 3–4
orders of magnitude higher than traditional
networks.
This is a new type of network that dynami-
cally provides an optical path to connect ter-
minal points between users through optical
switches. In order to realize this, the National
Institute of Advanced Industrial Science and
Technology has formed an R&D center to-
gether with ten collaborating organizations
to vertically integrate technologies such as
optical switches, system devices, network ar-
chitecture, and control systems. Development
of international researchers who are capable
of envisioning a wide scope on technologies
in areas ranging from devices to architecture
will also be carried out in the center.
( )President, National Institute of Advanced Industrial Science and Technology
RESEARCH THEME
5150
National Institute of Advanced Industrial Science and Technology (AIST)Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)
1 Development of Dynamic Optical Path Network
Study the architecture of a dynamic optical path network
that operates with an improvement in energy efficiency
over that of current networks on an order of 3–4 digits,
integrate the component technologies, and carry out val-
idation of the network.
Social Value Realize an information society that is able
to grow sustainably and in which large amounts of data,
such as for high definition images, can be used exten-
sively without being constrained by energy consumption
so as to change the economy, society, and living environ-
ment
Economic Value A network-related market to achieve an
ultra-large capacity at ultra-low energy consumption will
be formed. New applications markets will emerge, with
a great variety such as telepresence, ultra-high-definition
video-on-demand, etc..
Expected Market Scale/Expected Achievement Period
Approximately 1.2 trillion yen/10 years after end of im-
plementation period (in Japan)
Results to Date A study on the basic functions and con-
figuration of the nodes required for a dynamic optical
path network has been completed, and the construction
of a test bed has been started within the campus of the
AIST. The design based on a regular grid topology with 3
x 3 core nodes is ongoing, and a large-scale demonstra-
tion test to transmit an ultra high-definition 8K resolu-
tion video in real time will be carried out in Oct 2014.
Collaborating Organizations : Nippon Telegraph and Telephone Corporation, Fujitsu Laboratories Ltd., Furukawa Electric Co., Ltd., Trimatiz Ltd.,
NEC Corporation, Fujitsu Ltd, Fujikura Ltd., Alnair Labs Corporation, Sumitomo Electric Industries, Ltd., Kitanihon Electric Cable Co., Ltd.
3 Optical path processor
Develop an optical matrix switch based on silicon pho-
tonics that switches the optical path dynamically at the
fiber level and wavelength selection switches that switch
the optical path at the wavelength level.
Social Value As targeted in the overall concept, an in-
formation society that can grow sustainably will be real-
ized through the development of new switches.
Economic Value A new network-related market for opti-
cal devices to achieve ultra-large capacities at ultra-low
energy consumption will be formed.
Expected Market Scale/Expected Achievement Period
100 billion yen/10 years after end of implementation pe-
riod (in Japan)
Results to Date The world’s smallest PILOSS 8 x 8 optical
matrix switch has been produced successfully and its ba-
sic operations and performance have been verified.
Collaborating Organizations : Fujitsu Laboratories Ltd., NEC Corporation, Furukawa Electric Co., Ltd., Kitanihon Electric Cable Co., Ltd.
Collaborating Organizations : Nippon Telegraph and Telephone Corporation, NEC Corporation, Fujitsu Ltd, Sumitomo Electric Industries, Ltd.,
Interdisciplinary research that combines agriculture and engineering with the aim of material production (bio-production) that makes use of bio-resources as effectively as possible
At the “Innovative Bio Production Kobe (iBioK)” center, im-portant bio-products are rolled out in the market to realize green innovations and divert raw materials used from petro-leum to biomass.
Mass-produced next-generation fuel, synthesized raw mate-rials, bio-plastics, and bio-fibers, as well as high value-added bio-fine chemicals are three of the targeted product groups to be produced from biomass. Basic technologies that sup-port bio-production will also be commercialized so that they can be applied to even more chemicals.
Kobe University is the leading bio-refinery research authority in Japan. The agriculture and engineering faculties of the university will collaborate with 14 leading chemical compa-nies in Japan to build an international research center for accelerating the development of green innovations. Besides establishing the basic technologies for bio-production, the center will aim to commercialize important bio-products and become the core center for the formation of bio-combinates.
So far, the center has succeeded in raising the production volume of higher-order alcohols and organic acids by several times to several tens of times, and steady progress has been made towards commercialization through scale-up opera-tions. New fine chemicals and building blocks that will serve as new materials continue to be discovered in succession,
leading to the creation of new industries and new markets.
The 14 collaborating organizations are not simply a col-lection of companies. With Kobe University at the center, they collaborate closely with one another while shouldering different roles to form bio-combinates. This research center is an initiative to create Japan’s largest bio-refinery through industry-academia collaboration.
“Innovative Bio Production Kobe (iBioK)”
In-Depth Focus 12 Kobe University
11
In-Depth Focus 11
Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)
delivery through the abnormal post-translational modifi-
cation detected by the mass
spectrometer in this research
center. Furthermore, they found
abnormal c ircuit formation
and behaviours in isolated animals (Miyazaki et al. J. Clin.
Invest. 2012). Meanwhile, a rich environment facilitates
synaptic AMPA receptor delivery via the activation of sero-
tonergic system through the changes in phosphorylation
of AMPA receptors (Jitsuki et al. Neuron 2011). Further-
more, synaptic AMPA receptor delivery is required for the
formation of fear memory (Mitsushima et al. PNAS 2011,
Mitsushima et al. 2013 Nature Communications). Based
on these findings, leading compounds that control neural
plasticity were identified in cooperation with the organiza-
tions involved in this research center. This potentially leads
to clinical applications.
Pursuing the link between brain plasticity and neuropsychiatric disorders
10
Aim for the creation of a center that can conduct comprehensive research on the relationship between diseases and post-translational modifications in proteins using advanced proteomics analytical technologies.
Professor Takahashi
Kyoto University National Institute of Advanced Industrial Science and Technology (AIST)In-Depth Focus 09
09
Center for Innovation in Immunoregulatory Technology and Therapeutics (AK Project)
Under the slogan "Best Drugs on Best Science," Kyoto Univer-
sity and Astellas Pharma Inc. are collaborating to create new
innovative drugs in the immunology area including allergy such
as atopic dermatitis and pollinosis, autoimmune disorders such
as rheumatoid arthritis and SLE, cancer immunotherapy, and
immunosuppression in regenerative medicine.
In Japan, Kobe University is the only large research center for industry-academia collaboration
This center is the first in the world to promote everything from the development of an integrated bio-process to the formation of bio-combinates through industry-industry-academia collaboration